149 related articles for article (PubMed ID: 38443329)
1. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy.
Yang H; Zhang M; Ma G; Yang J; Wang K; Jiang S; Dong J; Han Y
Helicobacter; 2024; 29(2):e13059. PubMed ID: 38443329
[TBL] [Abstract][Full Text] [Related]
2. Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis.
Liu Z; Chen X; Sun DJ; Zhao WW; Kou L; Zheng WW; Hao JR; Gao FY
Medicine (Baltimore); 2024 Mar; 103(10):e37476. PubMed ID: 38457567
[TBL] [Abstract][Full Text] [Related]
3. Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Dong SQ; Singh TP; Wei X; Yao H; Wang HL
Helicobacter; 2017 Dec; 22(6):. PubMed ID: 28884937
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of vonoprazan-based regimen for Helicobacter pylori eradication: A meta-analysis of randomized clinical trials.
Yang C; Li S; Huang T; Lin H; Jiang Z; He Y; Yuan J; An H
J Clin Pharm Ther; 2022 Jul; 47(7):897-904. PubMed ID: 35247003
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial.
Chen C; Zhang D; Huang S; Zeng F; Li D; Zhang X; Chen R; Chen S; Wang J; Bai F
BMC Gastroenterol; 2024 Apr; 24(1):131. PubMed ID: 38609893
[TBL] [Abstract][Full Text] [Related]
6. Ten-Day Vonoprazan-Amoxicillin Dual Therapy vs Standard 14-Day Bismuth-Based Quadruple Therapy for First-Line Helicobacter pylori Eradication: A Multicenter Randomized Clinical Trial.
Yan TL; Wang JH; He XJ; Zhu YB; Lu LJ; Wang YJ; Wang ZW; Gao JG; Xu CF; Ma H; Luan SM; Li L; Chen Y
Am J Gastroenterol; 2024 Apr; 119(4):655-661. PubMed ID: 37975609
[TBL] [Abstract][Full Text] [Related]
7. Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial.
Lu L; Wang Y; Ye J; Han Y; Lou G; Li Y; Yan H; Du Q
Helicobacter; 2023 Feb; 28(1):e12940. PubMed ID: 36458325
[TBL] [Abstract][Full Text] [Related]
8. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.
Han S; Deng Z; Cheung K; Lyu T; Chan P; Li Y; Ni L; Luo X; Li K
BMC Gastroenterol; 2023 Jul; 23(1):231. PubMed ID: 37420205
[TBL] [Abstract][Full Text] [Related]
9. Vonoprazan is noninferior to proton pump inhibitors in bismuth-containing quadruple therapy for the treatment of Helicobacter pylori infection: A propensity score matching analysis.
Wang J; Li YY; Lin MJ; Liu J; Lin BS; Ding YM; Wan M; Zhang WL; Kong QZ; Wang ST; Mu YJ; Duan M; Han ZX; Zuo XL; Li YQ
J Dig Dis; 2023 Jan; 24(1):19-27. PubMed ID: 36960538
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication.
Huh KY; Chung H; Kim YK; Lee S; Bhatia S; Takanami Y; Nakaya R; Yu KS
Br J Clin Pharmacol; 2022 Jan; 88(1):138-144. PubMed ID: 34080718
[TBL] [Abstract][Full Text] [Related]
11. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
12. Vonoprazan on the Eradication of Helicobacter pylori Infection.
Huang J; Lin Y
Turk J Gastroenterol; 2023 Mar; 34(3):221-226. PubMed ID: 36511603
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of triple therapy containing berberine, amoxicillin, and vonoprazan for Helicobacter pylori initial treatment: A randomized controlled trial.
Chen S; Shen W; Liu Y; Dong Q; Shi Y
Chin Med J (Engl); 2023 Jul; 136(14):1690-1698. PubMed ID: 37469024
[TBL] [Abstract][Full Text] [Related]
14. Vonoprazan-amoxicillin dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Zhou BG; Jiang X; Ding YB; She Q; Li YY
Helicobacter; 2024; 29(1):e13040. PubMed ID: 37983865
[TBL] [Abstract][Full Text] [Related]
15. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis.
Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y
Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for
Lyu QJ; Pu QH; Zhong XF; Zhang J
Biomed Res Int; 2019; 2019():9781212. PubMed ID: 31211144
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, Safety, and Tolerability of Vonoprazan- or Esomeprazole-Based Bismuth-Containing Quadruple Therapy: A Phase 1, Double-Blind, Parallel-Group Study in Adults with Helicobacter pylori Infection in China.
Miao J; Hu C; Tang J; Wang W; Wang Y; Men R; Yang L; Gu L; Yoshida N; Czerniak R
Clin Pharmacol Drug Dev; 2023 Oct; 12(10):1036-1044. PubMed ID: 37443412
[TBL] [Abstract][Full Text] [Related]
18. Combination of vonoprazan and amoxicillin as the first-line Helicobacter pylori eradication therapy: a multicenter, prospective, randomized, parallel-controlled study.
Peng X; Chen HW; Wan Y; Su PZ; Yu J; Liu JJ; Lu Y; Zhang M; Yao JY; Zhi M
Clin Exp Med; 2023 Nov; 23(7):4011-4019. PubMed ID: 37115412
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of vonoprazan-based regimens compared with those of proton pump inhibitor (PPI)-based regimens as first-line agents for Helicobacter pylori: a meta-analysis of randomized clinical trials.
Sun Y; Yue L; Hu W
Eur J Clin Pharmacol; 2023 Feb; 79(2):279-288. PubMed ID: 36527456
[TBL] [Abstract][Full Text] [Related]
20. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy.
Qian HS; Li WJ; Dang YN; Li LR; Xu XB; Yuan L; Zhang WF; Yang Z; Gao X; Zhang M; Li X; Zhang GX
Am J Gastroenterol; 2023 Apr; 118(4):627-634. PubMed ID: 36729890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]